|Slideshows|May 3, 2016

Clinical Trial Highlights: AAN 2016 – Part 1

From no evidence of disease activity in MS to studies of a new treatment for periodic paralysis, AAN 2016 featured many exciting clinical trials.

Some of the best new research developments were highlighted at the Clinical Trials plenary session on April 20 during AAN 2016. In part 1 of this slideshow, we share results of the first four of eight trials featured. Natalia S. Rost, MD, Vice Chair of the Science Committee and Petra Kauffman, MS, member of the Science Committee, led the session.

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!

Clinical Trial Highlights: AAN 2016 – Part 1

Newsletter

Related Content

Expanding Neurology Care in South Miami: Peter Abdelmalik’s Vision

NeurologyLive® Friday 5 — November 28, 2025

Study Identifies Environmental Risk Factors Significantly Associated With Neuromyelitis Optica Spectrum Disorder

Natalizumab Biosimilar Officially Launched in the United States

Evolving Approaches to Seronegative NMOSD in New Diagnostic Criteria: Álvaro Cobo-Calvo, MD, PhD

Latest CME

Identifying and Treating CIDP in the Modern Era

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results

CTAD Presentation Lays Insights Into Disappointing Phase 3 EVOKE Trial of GLP-1 Semaglutide in Alzheimer Disease

US Survey Reveals Underuse of Dravet Syndrome–Specific Antiseizure Medications in the Clinic

Epidiolex CBD Treatment Effective Across Range of Developmental Epileptic Encephalopathies

AES Presentations Highlight Zorevunersen as Disease-Modifying Treatment for Dravet Syndrome